{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:41:46Z","timestamp":1790804506783,"version":"4.1.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"\n Purpose of review<\/jats:title>\n This review discusses the most updated literature of muscle disease in scleroderma in the past year.<\/jats:p>\n <\/jats:sec>\n \n Recent findings<\/jats:title>\n In the past year, two studies have highlighted that fibrosis is a prevalent histopathologic feature in muscle biopsies of patients with scleroderma muscle disease. In addition, microangiopathy was a common co-feature on muscle biopsies. A fibrosing myopathy, or fibrosis predominance on muscle histopathology, is associated with a unique clinical phenotype in patients with scleroderma. When compared with those with an inflammatory myopathy, patients with a fibrosing myopathy tend to have diffuse scleroderma, lower muscle enzymes, nonirritable myopathy, and elevated cardiac enzymes. These patients are also reported to have a higher risk of cardiopulmonary complications and cardiac death when compared with those with an inflammatory myopathy.<\/jats:p>\n <\/jats:sec>\n \n Summary<\/jats:title>\n Although there are clear cases of overlap myositis, it is clear that muscle disease in scleroderma is being redefined, and it is crucial to start recognizing that the muscle is an organ that can directly be affected by scleroderma. Fibrosis can occur early in scleroderma muscle disease, and a unique histologic subtype of muscle disease, fibrosing myopathy, is associated with a higher risk of mortality.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/bor.0000000000000552","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T01:20:21Z","timestamp":1535332821000},"page":"576-580","source":"Crossref","is-referenced-by-count":20,"title":["Muscle disease in scleroderma"],"prefix":"10.1097","volume":"30","author":[{"given":"Julie J.","family":"Paik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/art.1780110405","article-title":"Skeletal muscle involvement in progressive systemic sclerosis (scleroderma)","volume":"11","author":"Medsger","year":"1968","journal-title":"Arthritis Rheum"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/art.1780210111","article-title":"Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations","volume":"21","author":"Clements","year":"1978","journal-title":"Arthritis Rheum"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/ard.2008.095919","article-title":"A descriptive and prognostic study of systemic sclerosis-associated myopathies","volume":"68","author":"Ranque","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/archneur.1992.00530360094024","article-title":"Neurologic manifestations of progressive systemic sclerosis","volume":"49","author":"Averbuch-Heller","year":"1992","journal-title":"Arch Neurol"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/acr.22870","article-title":"Severity of muscle weakness independently associates with disability as measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI) in scleroderma","volume":"68","author":"Paik","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3899\/jrheum.121380","article-title":"The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review","volume":"40","author":"Muangchan","year":"2013","journal-title":"J Rheumatol"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3899\/jrheum.151425","article-title":"Patients with Systemic Sclerosis\/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It","volume":"43","author":"Bhansing","year":"2016","journal-title":"J Rheumatol"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03009742.2013.868512","article-title":"on behalf of the Canadian Scleroder. Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort","volume":"43","author":"Jung","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/acr.22620","article-title":"Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness","volume":"67","author":"Paik","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/ar4562","article-title":"Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology","volume":"16","author":"Bhansing","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10067-014-2730-z","article-title":"Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis","volume":"33","author":"Aguila","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3899\/jrheum.101248","article-title":"Clinical and serological hallmarks of systemic sclerosis overlap syndromes","volume":"38","author":"Pakozdi","year":"2011","journal-title":"J Rheumatol"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/acr.23291","article-title":"Association of fibrosing myopathy in systemic sclerosis and higher mortality","volume":"69","author":"Paik","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord NMD"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1759720X16671928","article-title":"Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation","volume":"9","author":"Corallo","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R17-20230901","first-page":"S12","article-title":"Anti-PM-Scl antibody in patients with systemic sclerosis","volume":"30","author":"Koschik","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T01:17:37Z","timestamp":1693531057000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201811000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000552","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}